Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Kenneth T. Mills net worth and biography

Kenneth Mills Biography and Net Worth

CEO of REGENXBIO

Ken Mills is the founding President and Chief Executive Officer of REGENXBIO. Prior to REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company. There, he served as a member of the founding management team, and worked to establish the company’s operations and ongoing business strategy. In this position, Mr. Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance and accounting activities. Prior to Meso Scale Diagnostics, he was Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.

What is Kenneth T. Mills' net worth?: The estimated net worth of Kenneth T. Mills is at least $6.40 million as of April 15th, 2024. Mr. Mills owns 408,035 shares of REGENXBIO stock worth more than $6,402,069 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Mills may own. Additionally, Mr. Mills receives a salary of $1,020,000.00 as CEO at REGENXBIO. Learn More about Kenneth T. Mills' net worth.
How old is Kenneth T. Mills?: Mr. Mills is currently 49 years old. There are 7 older executives and no younger executives at REGENXBIO. The oldest executive at REGENXBIO is Dr. Laura A. Coruzzi J.D., Ph.D., Executive Vice President of Intellectual Property, who is 70 years old. Learn More on Kenneth T. Mills' age.
What is Kenneth T. Mills' salary?: As the CEO of REGENXBIO Inc., Mr. Mills earns $1,020,000.00 per year. The highest earning executive at REGENXBIO is Mr. Patrick J. Christmas II, J.D., Executive VP & Chief Legal Officer, who commands a salary of $1,110,000.00 per year. Learn More on Kenneth T. Mills' salary.
How do I contact Kenneth T. Mills?: The corporate mailing address for Mr. Mills and other REGENXBIO executives is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. REGENXBIO can also be reached via phone at (240) 552-8181 and via email at [email protected]. Learn More on Kenneth T. Mills' contact information.
Has Kenneth T. Mills been buying or selling shares of REGENXBIO?: During the last ninety days, Kenneth T. Mills has sold $272,850.00 of REGENXBIO stock. Most recently, Kenneth T. Mills sold 15,000 shares of the business's stock in a transaction on Monday, April 15th. The shares were sold at an average price of $18.19, for a transaction totalling $272,850.00. Following the completion of the sale, the chief executive officer now directly owns 408,035 shares of the company's stock, valued at $7,422,156.65. Learn More on Kenneth T. Mills' trading history.
Who are REGENXBIO's active insiders?: REGENXBIO's insider roster includes Allan Fox (Director), Kenneth Mills (CEO), Kenneth Mills (CEO), and Steve Pakola (Insider). Learn More on REGENXBIO's active insiders.
Are insiders buying or selling shares of REGENXBIO?: In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 165,115 shares worth more than $3,085,821.51. The most recent insider tranaction occured on April, 15th when CEO Kenneth T Mills sold 15,000 shares worth more than $272,850.00. Insiders at REGENXBIO own 13.1% of the company. Learn More about insider trades at REGENXBIO.
Information on this page was last updated on 4/15/2024.

Kenneth T. Mills Insider Trading History at REGENXBIO

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/15/2024	Sell	15,000	$18.19	$272,850.00	408,035
3/14/2024	Sell	15,000	$21.86	$327,900.00	408,035
2/14/2024	Sell	15,000	$16.76	$251,400.00	408,035
1/16/2024	Sell	45,000	$15.18	$683,100.00	408,035
12/19/2023	Sell	45,000	$19.68	$885,600.00	355,289
11/8/2021	Sell	1,500	$40.00	$60,000.00
9/27/2021	Sell	1,500	$42.19	$63,285.00
6/24/2021	Sell	4,500	$40.02	$180,090.00	285,484
1/25/2021	Sell	6,500	$44.74	$290,810.00	287,484
1/7/2021	Sell	1,500	$50.01	$75,015.00	283,484
12/23/2020	Sell	4,500	$50.00	$225,000.00	245,500
12/16/2020	Sell	15,000	$45.00	$675,000.00	256,000
12/10/2020	Sell	4,500	$40.00	$180,000.00	245,500
9/19/2019	Sell	10,000	$39.75	$397,500.00	251,000
8/19/2019	Sell	15,000	$37.55	$563,250.00	261,000
7/19/2019	Sell	15,000	$49.49	$742,350.00	261,000
6/19/2019	Sell	15,000	$52.54	$788,100.00	261,000
5/20/2019	Sell	15,000	$42.99	$644,850.00	261,000
4/22/2019	Sell	15,000	$50.44	$756,600.00	261,000
3/19/2019	Sell	15,000	$58.53	$877,950.00	261,000
2/15/2019	Sell	15,000	$47.29	$709,350.00	261,000
1/15/2019	Sell	15,000	$43.85	$657,750.00	204,140
12/17/2018	Sell	15,000	$46.73	$700,950.00	223,396
11/26/2018	Sell	20,000	$64.17	$1,283,400.00	259,620
11/21/2018	Sell	15,000	$61.44	$921,600.00	284,700
11/12/2018	Sell	20,000	$63.11	$1,262,200.00
11/5/2018	Sell	20,000	$68.25	$1,365,000.00	322,500
10/15/2018	Sell	7,510	$59.35	$445,718.50	331,710
9/17/2018	Sell	7,510	$74.91	$562,574.10	339,505
8/27/2018	Sell	7,510	$66.46	$499,114.60	348,530
6/20/2018	Sell	5,000	$66.20	$331,000.00	208,330
5/21/2018	Sell	10,000	$47.05	$470,500.00
4/20/2018	Sell	10,000	$39.52	$395,200.00	219,430
3/20/2018	Sell	10,000	$29.55	$295,500.00	228,530
2/20/2018	Sell	10,000	$26.56	$265,600.00	238,530
1/22/2018	Sell	10,000	$27.33	$273,300.00	248,530
12/20/2017	Sell	10,000	$31.75	$317,500.00	108,530
11/20/2017	Sell	10,000	$27.71	$277,100.00
10/20/2017	Sell	10,000	$32.62	$326,200.00	98,730
9/20/2017	Sell	10,000	$29.33	$293,300.00	108,630
9/5/2017	Sell	10,500	$25.00	$262,500.00	118,530
8/21/2017	Sell	6,500	$20.05	$130,325.00	105,500
7/20/2017	Sell	6,500	$18.66	$121,290.00	112,000
6/20/2017	Sell	6,500	$19.68	$127,920.00	119,396
4/24/2017	Sell	15,440	$20.98	$323,931.20	126,395

Kenneth T. Mills Buying and Selling Activity at REGENXBIO

REGENXBIO Company Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Today's Range

Now: $15.69

$15.32

$16.26

50 Day Range

MA: $20.02

$15.69

$24.61

2 Week Range

Now: $15.69

$11.83

$28.80

Volume

574,896 shs

Average Volume

733,667 shs

Market Capitalization

$769.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

Kenneth Mills Biography and Net Worth

What is Kenneth T. Mills' net worth?

How old is Kenneth T. Mills?

What is Kenneth T. Mills' salary?

How do I contact Kenneth T. Mills?

Has Kenneth T. Mills been buying or selling shares of REGENXBIO?

Who are REGENXBIO's active insiders?

Are insiders buying or selling shares of REGENXBIO?